Thermo Fisher Scientific ADAR Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 0.04–0.4 µg/mL

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 1:500–1:1,000

Immunocytochemistry (ICC/IF)

• Tested Dilution: 0.25–2 µg/mL

Product Specifications

Product Specific Information

Immunogen sequence:
SDNQPEGMIS ESLDNLESMM PNKVRKIGEL VRYLNTNPVG GLLEYARSHG FAAEFKLVDQ SGPPHEPKFV YQAKVGGRWF PAVCAHSKKQ GKQEAADAAL RVLIGENEKA ERMGFTEVTP VTGASLRRTM LLLSRSPEA

Antigen sequence identity:

• Mouse: 86%
• Rat: 85%

Target Information

Adenosine Deaminase RNA Specific (ADAR) catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA), referred to as A-to-I RNA editing. This process can affect gene expression and function through:

• mRNA translation (codon changes leading to altered proteins)
• pre-mRNA splicing (splice site recognition changes)
• RNA stability (nuclease recognition sequence changes)
• genetic stability in RNA virus genomes
• RNA structure-dependent activities (microRNA production, protein-RNA interactions)

ADAR edits both viral and cellular RNAs, either at multiple sites (hyper-editing) or specific sites (site-specific editing).
Cellular RNA substrates: BLCAP, GRIA2, HTR2C, GABRA3
Viral RNA substrates: HCV, VSV, MV, HDV, HIV-1

ADAR exhibits variable effects depending on the virus type:

• Antiviral: HCV (editing-dependent)
• Proviral: HDV, MV, VSV, HIV-1 (editing-dependent or independent)

It modulates viral replication through mechanisms involving EIF2AK2/PKR suppression and A-to-I editing at specific viral RNA sites.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

제품 이미지

(이미지 없음)